In-vitro effect of pembrolizumab on different T regulatory cell subsets

Muhammd Toor, A. S. Syed Khaja, I. Alkurd, Eyad Elkord

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Programmed death-1 (PD-1) and interactions with PD-ligand 1 (PD-L1) play critical roles in the tumour evasion of immune responses through different mechanisms, including inhibition of effector T cell proliferation, reducing cytotoxic activity, induction of apoptosis in tumour-infiltrating T cells and regulatory T cell (Treg) expansion. Effective blockade of immune checkpoints can therefore potentially eliminate these detrimental effects. The aim of this study was to investigate the effect of anti-PD-1 antibody, pembrolizumab, on various Treg subpopulations. Peripheral blood mononuclear cells (PBMC) from healthy donors (HD) and primary breast cancer patients (PBC) were treated in vitro with pembrolizumab, which effectively reduced PD-1 expression in both cohorts. We found that PD-1 was expressed mainly on CD4+CD25+ T cells and pembrolizumab had a greater effect on PD-1 expression in CD4+CD25 T cells, compared to CD4+CD25+ cells. In addition, pembrolizumab did not affect the expression levels of Treg-related markers, including cytotoxic T lymphocyte antigen-4 (CTLA-4), CD15s, latency-associated peptide (LAP) and Ki-67. Moreover, we report that CD15s is expressed mainly on forkhead box P3 (FoxP3)Helios+ Treg in HD, but it is expressed on FoxP3+Helios Treg subset in addition to FoxP3Helios+ Treg in PBC. Pembrolizumab did not affect the levels of FoxP3+/−Helios+/− Treg subsets in both cohorts. Taken together, our study suggests that pembrolizumab does not affect Treg or change their phenotype or function but rather blocks signalling via the PD-1/PD-L1 axis in activated T cells.

Original languageEnglish
Pages (from-to)189-197
Number of pages9
JournalClinical and Experimental Immunology
Volume191
Issue number2
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

T-Lymphocyte Subsets
T-Lymphocytes
Tissue Donors
CTLA-4 Antigen
Breast Neoplasms
Tumor Escape
Ligands
Regulatory T-Lymphocytes
pembrolizumab
In Vitro Techniques
Blood Cells
Cell Proliferation
Apoptosis
Phenotype
Peptides
Antibodies
Neoplasms

Keywords

  • cancer
  • regulatory T cells
  • T cells
  • tumour immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

In-vitro effect of pembrolizumab on different T regulatory cell subsets. / Toor, Muhammd; Syed Khaja, A. S.; Alkurd, I.; Elkord, Eyad.

In: Clinical and Experimental Immunology, Vol. 191, No. 2, 01.01.2018, p. 189-197.

Research output: Contribution to journalArticle

@article{a798ed015b1a4b12bf6d9f88b4649477,
title = "In-vitro effect of pembrolizumab on different T regulatory cell subsets",
abstract = "Programmed death-1 (PD-1) and interactions with PD-ligand 1 (PD-L1) play critical roles in the tumour evasion of immune responses through different mechanisms, including inhibition of effector T cell proliferation, reducing cytotoxic activity, induction of apoptosis in tumour-infiltrating T cells and regulatory T cell (Treg) expansion. Effective blockade of immune checkpoints can therefore potentially eliminate these detrimental effects. The aim of this study was to investigate the effect of anti-PD-1 antibody, pembrolizumab, on various Treg subpopulations. Peripheral blood mononuclear cells (PBMC) from healthy donors (HD) and primary breast cancer patients (PBC) were treated in vitro with pembrolizumab, which effectively reduced PD-1 expression in both cohorts. We found that PD-1 was expressed mainly on CD4+CD25+ T cells and pembrolizumab had a greater effect on PD-1 expression in CD4+CD25− T cells, compared to CD4+CD25+ cells. In addition, pembrolizumab did not affect the expression levels of Treg-related markers, including cytotoxic T lymphocyte antigen-4 (CTLA-4), CD15s, latency-associated peptide (LAP) and Ki-67. Moreover, we report that CD15s is expressed mainly on forkhead box P3 (FoxP3)−Helios+ Treg in HD, but it is expressed on FoxP3+Helios− Treg subset in addition to FoxP3−Helios+ Treg in PBC. Pembrolizumab did not affect the levels of FoxP3+/−Helios+/− Treg subsets in both cohorts. Taken together, our study suggests that pembrolizumab does not affect Treg or change their phenotype or function but rather blocks signalling via the PD-1/PD-L1 axis in activated T cells.",
keywords = "cancer, regulatory T cells, T cells, tumour immunology",
author = "Muhammd Toor and {Syed Khaja}, {A. S.} and I. Alkurd and Eyad Elkord",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/cei.13060",
language = "English",
volume = "191",
pages = "189--197",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - In-vitro effect of pembrolizumab on different T regulatory cell subsets

AU - Toor, Muhammd

AU - Syed Khaja, A. S.

AU - Alkurd, I.

AU - Elkord, Eyad

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Programmed death-1 (PD-1) and interactions with PD-ligand 1 (PD-L1) play critical roles in the tumour evasion of immune responses through different mechanisms, including inhibition of effector T cell proliferation, reducing cytotoxic activity, induction of apoptosis in tumour-infiltrating T cells and regulatory T cell (Treg) expansion. Effective blockade of immune checkpoints can therefore potentially eliminate these detrimental effects. The aim of this study was to investigate the effect of anti-PD-1 antibody, pembrolizumab, on various Treg subpopulations. Peripheral blood mononuclear cells (PBMC) from healthy donors (HD) and primary breast cancer patients (PBC) were treated in vitro with pembrolizumab, which effectively reduced PD-1 expression in both cohorts. We found that PD-1 was expressed mainly on CD4+CD25+ T cells and pembrolizumab had a greater effect on PD-1 expression in CD4+CD25− T cells, compared to CD4+CD25+ cells. In addition, pembrolizumab did not affect the expression levels of Treg-related markers, including cytotoxic T lymphocyte antigen-4 (CTLA-4), CD15s, latency-associated peptide (LAP) and Ki-67. Moreover, we report that CD15s is expressed mainly on forkhead box P3 (FoxP3)−Helios+ Treg in HD, but it is expressed on FoxP3+Helios− Treg subset in addition to FoxP3−Helios+ Treg in PBC. Pembrolizumab did not affect the levels of FoxP3+/−Helios+/− Treg subsets in both cohorts. Taken together, our study suggests that pembrolizumab does not affect Treg or change their phenotype or function but rather blocks signalling via the PD-1/PD-L1 axis in activated T cells.

AB - Programmed death-1 (PD-1) and interactions with PD-ligand 1 (PD-L1) play critical roles in the tumour evasion of immune responses through different mechanisms, including inhibition of effector T cell proliferation, reducing cytotoxic activity, induction of apoptosis in tumour-infiltrating T cells and regulatory T cell (Treg) expansion. Effective blockade of immune checkpoints can therefore potentially eliminate these detrimental effects. The aim of this study was to investigate the effect of anti-PD-1 antibody, pembrolizumab, on various Treg subpopulations. Peripheral blood mononuclear cells (PBMC) from healthy donors (HD) and primary breast cancer patients (PBC) were treated in vitro with pembrolizumab, which effectively reduced PD-1 expression in both cohorts. We found that PD-1 was expressed mainly on CD4+CD25+ T cells and pembrolizumab had a greater effect on PD-1 expression in CD4+CD25− T cells, compared to CD4+CD25+ cells. In addition, pembrolizumab did not affect the expression levels of Treg-related markers, including cytotoxic T lymphocyte antigen-4 (CTLA-4), CD15s, latency-associated peptide (LAP) and Ki-67. Moreover, we report that CD15s is expressed mainly on forkhead box P3 (FoxP3)−Helios+ Treg in HD, but it is expressed on FoxP3+Helios− Treg subset in addition to FoxP3−Helios+ Treg in PBC. Pembrolizumab did not affect the levels of FoxP3+/−Helios+/− Treg subsets in both cohorts. Taken together, our study suggests that pembrolizumab does not affect Treg or change their phenotype or function but rather blocks signalling via the PD-1/PD-L1 axis in activated T cells.

KW - cancer

KW - regulatory T cells

KW - T cells

KW - tumour immunology

UR - http://www.scopus.com/inward/record.url?scp=85032896039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032896039&partnerID=8YFLogxK

U2 - 10.1111/cei.13060

DO - 10.1111/cei.13060

M3 - Article

VL - 191

SP - 189

EP - 197

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -